Regulatory Reliance on Post-Market Surveillance Data Legality

Introduction

Post-market surveillance (PMS) is the continuous monitoring of medicines, vaccines, medical devices and biological products after they receive regulatory approval. It helps identify risks that may not have been detected during clinical trials, including rare adverse effects, long-term complications and safety concerns arising from widespread use.

Regulatory reliance on PMS data means that a regulator uses evidence from adverse-event reports, patient registries, observational studies, real-world data and foreign surveillance systems to make decisions. Such reliance is legally permissible, provided that the data are reliable, relevant and assessed within the regulator’s statutory powers. PMS evidence may support continued approval, label changes, restrictions, suspension or withdrawal.

Legal Framework in India

The legal basis is found in the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019. The regulatory framework requires manufacturers and marketing authorisation holders to maintain pharmacovigilance systems and report adverse drug reactions.

Under the applicable PMS requirements, Periodic Safety Update Reports (PSURs) must communicate new safety information, relate findings to patient exposure, and assess whether product information or warnings require revision. Serious unexpected adverse reactions may trigger expedited reporting and regulatory review.

CDSCO+2

The Central Drugs Standard Control Organization (CDSCO) and the Pharmacovigilance Programme of India (PvPI) collect and assess adverse-event information. Such evidence may justify changes to approved labels, warnings, use restrictions or other safety measures.

Indian Postal Circle+1

Legality of Reliance on PMS Data

Reliance on PMS data is lawful and necessary because pre-approval clinical trials may involve limited participants and follow-up periods. However, post-market reports must be interpreted carefully:

Causality: A reported event does not automatically prove that a medicine caused it.

Data quality: Regulators should consider completeness, duplication, reporting bias and patient exposure.

Risk-benefit assessment: Decisions should consider the seriousness and frequency of the suspected risk alongside therapeutic benefits.

Procedural fairness: Where regulatory action adversely affects a licence holder, the authority should act within its statutory powers and follow applicable procedural requirements.

The regulator may act on a credible safety signal even before causation is conclusively established, particularly where public health is at risk. The strength of evidence and proportionality of the action remain important.

Relevant Case Laws

1. Mohinder Singh Gill v. Chief Election Commissioner, (1978) 1 SCC 405

The Supreme Court held that a statutory administrative order must be judged by the reasons stated in the order and cannot ordinarily be improved later through fresh explanations. Applied by analogy, regulatory decisions based on PMS data should record the relevant evidence and reasoning rather than rely on unsupported assertions.

2. A.P. v. McDowell & Co., (1996) 3 SCC 709

The Supreme Court emphasised that an action is not invalid merely because it is considered unreasonable; illegality must be assessed against the governing law. In the PMS context, regulatory reliance must be tested against statutory authority, applicable rules and procedural requirements.

3. Jacob Puliyel v. Union of India, 2022 SCC OnLine SC 533

The Supreme Court considered vaccine safety, regulatory review and public-health concerns during the COVID-19 pandemic. The judgment illustrates the importance of scientific evidence and regulatory assessment in vaccine-related decisions. It is relevant by analogy, although it is not a direct ruling on the legal use of all PMS datasets.

These cases provide general administrative and public-health principles; they do not establish a specific judicial test for every form of PMS data.

Conclusion

Regulatory reliance on post-market surveillance data is legally justified and essential for continuing product safety. In India, statutory pharmacovigilance duties and PSUR requirements support such reliance. However, regulators must assess data quality, consider causality and benefit-risk balance, and provide reasoned, proportionate action. The governing principle is evidence-based surveillance without arbitrary regulatory decision-making.